

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LANSEN PHARMACEUTICAL HOLDINGS LIMITED

朗生醫藥控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 503)

**RESIGNATION OF NON-EXECUTIVE DIRECTOR
AND MEMBER OF THE REMUNERATION COMMITTEE**

The board of directors (the “**Board**”) of Lansen Pharmaceutical Holdings Limited (the “**Company**”) hereby announces that Mr. Stephen Burnau Hunt (“**Mr. Hunt**”), after having served on the Board for 12 years, has retired as a Non-executive Director and a member of the Remuneration Committee of the Company with effect from 9 April 2022.

Mr. Hunt has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company.

The Chairman and the Board express their sincere gratitude to Mr. Hunt for his service and valuable contribution made to the Company.

By order of the Board
Lansen Pharmaceutical Holdings Limited
Wu Zhen Tao
Chairman

Hong Kong, 11 April 2022

As at the date of this announcement, the executive managing Director is Mr. Chen Li; the non-executive Directors are Mr. Wu Zhen Tao and Ms. Liu Xuezi; the independent non-executive Directors are Mr. Chan Kee Huen, Michael, Mr. Yeung Tak Bun, Allen and Ms. Chan Ching Har Eliza.